Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies

Abstract: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Since the discovery that the KIT and PDGFRA receptor tyrosine kinases are the primary oncogenic drivers in the vast majority of GISTs, targeted therapy with tyrosine kinase inhibitors has been the mainstay of treatment for this disease. Using molecular profiling of tumor specimens, researchers also discovered that KIT and PDGFRA mutations are non-random and occur in specific regions of the receptors, and furthermore, that particular genotypes predicted response or resistance to targeted therapy. Imatinib, the first tyrosine kinase inhibitor used to treat GIST, remains the first-line therapy in advanced GIST and the only therapy confirmed through clinical trials in the adjuvant or neoadjuvant setting for resectable disease. Resistance to imatinib is well described and is either primary or secondary. Primary resistance is associated with specific tumor genotypes, so genotyping of individual patient tumors helps guide decision-making into whether to offer imatinib and at what dose. Secondary resistance occurs due to the acquisition of secondary mutations during therapy. Currently, the main strategy to combat imatinib resistance is to switch to another tyrosine kinase inhibitor, because imatinib-resistant GIST is usually still oncogenically addicted to KIT/PDGFRα signaling. Surgery can also be used to combat resistant disease in select settings. Unfortunately, progression-free and overall survival remains dismal for patients who develop imatinib-resistant disease, and further research into alternative strategies is still needed.

Keywords: GIST, targeted therapy, tyrosine kinase inhibitor, imatinib

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract, with an incidence of 3,000–5,000 cases per year in the United States. GISTs arise from the interstitial cells of Cajal (ICC), which are intestinal pacemaker cells. ICCs require the KIT receptor tyrosine kinase for normal development, but constitutively active KIT signaling has been shown in multiple studies to be the central driving force behind GIST tumorigenesis. Indeed, based on this biological framework, most current-targeted therapy strategies against GIST are aimed against KIT and its related receptor tyrosine kinases. In this review, we will discuss the molecular basis of targeted therapy and personalized medicine in GIST, current treatment paradigms, mechanisms of resistance, strategies to overcome resistance, and novel research into alternative approaches.
Molecular characteristics of GIST

Over 90% of GISTs stain positive for KIT on immunohistochemistry, and approximately 70–85% of tumors with sequencing data have an identifiable gain-of-function KIT mutation. KIT is a 145 kDa transmembrane glycoprotein in the receptor tyrosine kinase family that consists of an extracellular domain (encoded by exons 1–9), a transmembrane domain (exon 10), a juxtamembrane domain (exon 11), and a tyrosine kinase domain (exons 13–21). Its most well-described ligand is stem cell factor (SCF), which causes receptor dimerization and activation. Following KIT activation, subsequent downstream signaling via phosphoinositide 3-kinase (PI3K), Src kinase, and mitogen-activated protein kinase result in cellular differentiation, proliferation, and survival (Figure 1). While normal KIT signaling is required for ICC differentiation and survival, constitutive ligand-independent KIT activation leads to GIST tumorigenesis.

Over 60% of mutations in GIST are located in KIT exon 11, which encodes the juxtamembrane domain responsible for inhibiting receptor dimerization and activation in the absence of SCF ligand (Figure 2). Another 20% of mutations are in KIT exon 9 in the extracellular domain, which also cause ligand-independent receptor activation.

Figure 1 KIT and PDGFRA downstream signaling pathways.
Abbreviations: SCF, stem cell factor; PDGF, platelet-derived growth factor; JNK, c-Jun N-terminal kinase; PI3K, phosphoinositide 3-kinase; mTOR, mammalian target of rapamycin; MEK, mitogen-activated protein kinase; MAPK, mitogen-activated protein kinase.
dimerization. Less common mutations have also been described in other regions of KIT, although these are usually seen as secondary mutations in tumors exposed to tyrosine kinase inhibitors as opposed to treatment-naïve tumors, as will be discussed later.\(^6\)

Approximately 10–15% of GISTs have an activating mutation in PDGFRA, another receptor tyrosine kinase closely related in both structure and chromosomal gene location to KIT (Figure 2).\(^7\) The most common PDGFRA mutations are located in exon 18 (the activation loop of the tyrosine kinase domain) and exon 12 (the juxtamembrane domain).\(^7,15\) There is significant overlap in signaling pathways downstream of KIT and PDGFRA in GIST, suggesting that these two receptors provide alternative entries into a common tumorigenic pathway. In fact, activating mutations of KIT and PDGFRA appear to be mutually exclusive.\(^7\) However, fundamental biological differences do seem to exist between these two types of GISTs, as gene expression profiles of KIT-mutant GISTs differ from those of PDGFRA-mutant GISTs,\(^8\) and PDGFRA-mutant GISTs occur almost exclusively in the stomach.\(^19\)

Finally, there remains a small group of GISTs that do not have any detectable mutations in either KIT or PDGFRA, previously termed "wild-type" GIST, which constitutes approximately 10% of adult GISTs but up to 85% of pediatric GISTs.\(^20\) Most of these tumors are now recognized to have a deficiency in succinyl dehydrogenase (SDH) activity.

A study from the National Institutes of Health found that 66% of wild-type GIST had loss-of-function SDH mutations, and 22% had methylation of the SDHC promoter which led to epigenetic silencing of SDH expression. Most of the remaining 12% of patients with SDH-competent tumors either had NF1 (usually patients with type 1 neurofibromatosis also called von Recklinghausen neurofibromatosis) or BRAF V600E mutations, with only a small minority having an idiopathic tumorigenic mechanism.\(^21\)

**Targeted therapy and mechanisms of drug resistance**

**Imatinib**

Given the central role of KIT and its related receptor tyrosine kinase PDGFRA in GIST tumorigenesis, current targeted therapies are tyrosine kinase inhibitors primarily aimed at one or both of these receptors. The first anti-KIT therapy for GIST was imatinib, a tyrosine kinase inhibitor used initially for chronic myelogenous leukemia that was subsequently found to also have anti-KIT and anti-PDGFRA activity.\(^5\) Demetri and colleagues assessed the efficacy of imatinib in 147 patients with unresectable or metastatic GIST, and found a remarkable partial response rate of over 50%, with an additional 28% of patients achieving stable disease.\(^22\) Further Phase II and Phase III studies confirmed the long-term efficacy of imatinib in...
patients with advanced GIST, with reported median overall survivals of over 4 years. This success in patients led to studies of adjuvant imatinib in patients with resectable primary GIST. The American College of Surgeons Oncology Group (ACOSOG) Z9001 trial enrolled 713 patients with completely resected GIST at least 3 cm in diameter with KIT positivity on immunohistochemistry, and randomized them to either adjuvant imatinib therapy or placebo for 1 year. Patients in the imatinib group had a significantly improved 1-year recurrence-free survival (RFS) of 98% compared to 83% in the control group. A follow-up analysis of a subgroup of 645 patients with available tumor specimens to assess mitotic rate and mutational profiles found that large tumor size, small bowel location, and high mitotic rate were associated with lower RFS within both the placebo and imatinib arms. In addition, patients with KIT exon 11 deletions had improved RFS with adjuvant imatinib compared to placebo.

Subsequent trials have examined whether longer durations of adjuvant therapy provide additional benefit. The Scandinavian Sarcoma Group (SSG) XVIII trial randomized 400 patients with resected GIST with high-risk features to 3 years versus 1 year of adjuvant imatinib. They found that patients who had 3 years of adjuvant imatinib had significantly better RFS and importantly overall survival (OS) than patients who had 1 year of adjuvant imatinib. A subsequent analysis of data from this trial of 341 patients with mutation data found that most of the survival benefit was realized by patients with KIT exon 11 mutations and that patients with wild-type GIST or other KIT or PDGFRA mutations did not derive benefit from the longer duration of adjuvant imatinib.

Based on SSG XVIII, the current standard-of-care duration for adjuvant imatinib in resected high-risk GIST is at least 3 years (Figure 3), but it is possible that patients may derive additional benefit from even longer therapy provided they do not have a known mutation conferring imatinib resistance. A recent single-arm Phase II trial, PERSIST-5, examined tolerability and efficacy of 5 years of adjuvant imatinib in patients with resected GIST’s with intermediate-risk or high-risk features. The authors reported a 5-year RFS of 90% and 5-year OS of 95%. The only patient who recurred on adjuvant imatinib had a PDGFRA D842V mutation, which, as will be discussed, is associated with imatinib resistance. All other recurrences occurred after discontinuation of imatinib.

Imatinib therapy in the neoadjuvant setting is less well established. RTOG 0132/ACRIN 6665 was a Phase II trial that enrolled 63 patients with resectable primary GIST at least 5 cm in diameter or recurrent/metastatic GIST at least 2 cm in diameter. Patients received 8–12 weeks of neoadjuvant imatinib at 600 mg daily, followed by surgery. The study authors noted low rates of postoperative complications and a post-operative mortality rate of 2.2%, confirming the safety of imatinib use in the neoadjuvant setting. However, one criticism of this trial is that the neoadjuvant treatment duration was too short to see a response, and indeed only 7% of resectable primary tumors and 4.5% of recurrent/metastatic tumors had partial responses to neoadjuvant therapy. Another multicenter Phase II trial in Asia examined longer neoadjuvant imatinib therapy in 53 patients with gastric GIST’s at least 10 cm in diameter. Patients were treated with imatinib for at least 6 months, with extension to 9 months if there was a complete or partial response, unless the tumor progressed at 1 or 3 months at which point neoadjuvant treatment was stopped and the patient proceeded to surgery. Of the 53 patients, 46 received at least 6 months of neoadjuvant therapy, 33 (62%) had a partial response, and 91% (48/53) received an R0 resection. Of note, other than 1 patient who was excluded from the Asian trial for a PDGFRA D842V mutation, there were no other mentions of mutation status in either of the neoadjuvant trials. Overall, neoadjuvant therapy seems to be safe, and may be especially useful for esophageal, duodenal, and rectal GISTs, as pre-operative tumor shrinkage may facilitate sphincter/organ preservation and negative margins based on retrospective series. Unfortunately, there are no randomized trials.
that examine the effect of neoadjuvant therapy on RFS or OS.

Resistance to imatinib

Imatinib resistance is a well-described problem in GIST. Resistance is characterized as primary resistance, in which the tumor progresses through an initial imatinib challenge, or secondary resistance, in which the tumor progresses after an initial period of stabilization or response to imatinib. Several GIST genotypes are associated with primary resistance. For example, patients with KIT exon 9 mutations were much less likely to respond to imatinib than those with KIT exon 11 mutations, though response rates could be improved by increasing imatinib dosing from 400 mg daily to 800 mg daily. KIT exon 9 mutations cause receptor dimerization in the absence of ligand in a conformation that may sterically hinder imatinib binding. The PDGFRA D842V mutation, located in exon 18 in the activation loop, is also associated with imatinib resistance, although most of these tumors seem to have low mitotic rates and an indolent clinical course. Cassier and colleagues examined 58 patients with PDGFRA-mutant GIST’s treated with imatinib. There were no responses among patients with PDGFRA D842V, and only 32% of these patients achieved stable disease as their best response. Laboratory studies have shown that the D842V mutation diminishes accessibility of imatinib’s binding site to PDGFRA. Wild-type tumors also tend to be resistant to imatinib, but they also tend to have an indolent overall clinical course.

The development of secondary resistance usually occurs through the acquisition of secondary mutations. Unlike primary mutations, which usually occur in exons 9 and 11, secondary mutations most often occur in exons 13 and 14 of the ATP binding pocket of the tyrosine kinase domain, and in exons 17 and 18 of the activation loop of the tyrosine kinase domain. Antonescu and colleagues examined 31 patients with GIST who were treated with imatinib prior to surgical resection, of which 15 had developed secondary resistance. Seven (46%) of these patients developed secondary mutations, and while the primary KIT mutations in these patients were all in either exons 9 or 11, secondary KIT mutations occurred in exon 17 (6 of 7 patients), and exons 13 and 14 (1 patient each). Another study by Heinrich and colleagues examined genetic profiles of pre- and post-imatinib treatment tumor samples from 78 patients with metastatic GIST, and found secondary mutations in 33 patients. Sixteen patients had exon 13 mutations, three patients had exon 14 mutations, 12 patients had exon 17 mutations, and two patients had exon 18 mutations, with one patient having both an exon 13 and exon 17 mutation. Exon 14 mutations are thought to disrupt an H-bond involved in imatinib binding, while other secondary mutations are thought to stabilize KIT in a conformation that imatinib cannot bind efficiently.

Strategies to overcome drug resistance

Switch tyrosine kinase inhibitors

Interestingly, imatinib resistance does not correlate with KIT activity, and cell lines derived from imatinib-resistant GISTs still rely on KIT to activate downstream signaling, suggesting that these tumors may still rely on KIT activation for survival and proliferation. Thus, the primary strategy for overcoming imatinib resistance is to switch to another tyrosine kinase inhibitor (Figure 4).

Sunitinib is currently established as the second-line tyrosine kinase inhibitor for patients with GIST refractory to imatinib. It has activity against KIT, PDGFRA, and also against vascular endothelial growth factor receptor (VEGFR). A randomized double-blinded clinical trial by Demetri and colleagues compared sunitinib to placebo in 312 patients with metastatic or unresectable GIST who were resistant to or intolerant of previous treatment with imatinib. Patients treated with sunitinib had significantly improved median progression-free survival (PFS, 27.3 weeks vs 6.4 weeks), although the best response achieved by the vast majority of patients in the sunitinib group was stable disease, as only 7% of patients in the sunitinib group had a partial response and there were no complete responders. Patients with KIT exon 9 mutations had higher response rates to sunitinib than patients with KIT exon 11 mutations, and patients with secondary KIT exon 13 or 14 mutations had higher response rates compared to patients with secondary KIT exon 17 or 18 mutations.

Regorafenib, another tyrosine kinase inhibitor with broad activity against KIT, PDGFRA, VEGFR, and BRAF, is third-line therapy for patients with GIST refractory to both imatinib and sunitinib. A Phase III clinical trial, also by Demetri and colleagues, of 199 GIST patients refractory to or intolerant of imatinib and sunitinib randomized to regorafenib or best supportive care showed a significantly improved PFS with regorafenib (4.8 months vs 0.9 months). Again, similar to sunitinib, there were no complete responders and only 4.5% of patients achieved a partial response on regorafenib.
For patients with progression on regorafenib, other tyrosine kinase inhibitors such as nilotinib,\textsuperscript{49} pazopanib,\textsuperscript{50} dasatinib,\textsuperscript{51,52} or sorafenib\textsuperscript{53} can be considered. Table 1 summarizes the current list of tyrosine kinase inhibitors used for GIST. These agents have all shown some efficacy in imatinib and sunitinib-resistant GIST in Phase I and Phase II clinical trials, although times to progression are all on the order of months, and partial response rates are uniformly low. The low patient numbers in these trials only allow for limited assessment of associations between mutation status and response to therapy. Thus, decisions to treat patients with these further line tyrosine kinase inhibitors are empiric and not necessarily genotype-based.

Another option for patients with GIST that progressed on imatinib and then sunitinib is to re-challenge them with imatinib. The RIGHT trial was a Phase III trial that randomized 81 patients with metastatic or unresectable GIST who progressed on at least both imatinib and sunitinib to imatinib re-challenge or placebo.\textsuperscript{54} Median PFS was statistically significantly higher in the imatinib-treated group.

### Table 1 Tyrosine kinase inhibitors currently used to treat GIST

<table>
<thead>
<tr>
<th>Line of therapy</th>
<th>Trial demonstrating efficacy</th>
<th>N</th>
<th>Median time to progression (months)</th>
<th>Partial response</th>
<th>Stable disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imatinib</td>
<td>First</td>
<td>147</td>
<td>24</td>
<td>54%</td>
<td>28%</td>
</tr>
<tr>
<td></td>
<td>Second</td>
<td>207</td>
<td>6.1 (27.3 weeks)</td>
<td>7%</td>
<td>58%</td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Third or later</td>
<td>133</td>
<td>4.8</td>
<td>5%</td>
<td>71%</td>
</tr>
<tr>
<td>Regorafenib</td>
<td></td>
<td>40</td>
<td>3.4</td>
<td>0%</td>
<td>84%</td>
</tr>
<tr>
<td>Pazopanib</td>
<td>First</td>
<td>42</td>
<td>13.6</td>
<td>13%</td>
<td>52%</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Third or later</td>
<td>31</td>
<td>4.9</td>
<td>13%</td>
<td>52%</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>First</td>
<td>50</td>
<td>2.9</td>
<td>74%</td>
<td>14%</td>
</tr>
<tr>
<td></td>
<td>Second or later</td>
<td>42</td>
<td></td>
<td>25%</td>
<td>NR</td>
</tr>
<tr>
<td>Nilotinib</td>
<td>Third or later</td>
<td>165</td>
<td>4 (119 days)</td>
<td>&lt;1%</td>
<td>53%</td>
</tr>
</tbody>
</table>

Note: \textsuperscript{a}Response measured by FDG-PET avidity.

Abbreviations: N, number of patients; NR, not reported; GIST, gastrointestinal stromal tumor.
but was only 1.8 months, compared to 0.9 months on placebo.

**Metastasectomy**

As discussed previously, tumors exposed to imatinib develop secondary mutations that confer resistance. Thus, another strategy has been to surgically debulk metastatic disease with the hope of removing resistant clones, removing as much stable or responding disease as is feasible to minimize the development of secondary resistance, and prolonging time to progression. However, data on the efficacy of surgery in patients with metastatic GIST on tyrosine kinase inhibitors are limited to retrospective studies.55–61 A Phase III trial in China attempted to determine if patients undergoing metastasectomy while on imatinib therapy had better outcomes compared to those maintained on drug alone, but closed due to poor accrual (41 of a planned 210 patients).62 There was no significant difference in PFS, though there was a trend favoring surgery (2-year PFS 88.4% vs 57.7%, \(P=0.089\)). There was a difference in median OS favoring surgery (not reached vs 49 months, \(P=0.024\)), but that was not the primary endpoint. The European Organization for Research and Treatment of Cancer (EORTC) also sought to conduct a randomized controlled trial to determine whether surgery provided additional benefit to patients with metastatic GIST on imatinib (NCT00956072). Unfortunately, the trial was terminated due to low accrual.

The largest retrospective series comes from Brigham and Women’s Hospital/Dana-Farber Cancer Institute and Memorial-Sloan Kettering Cancer Center, which included 400 resections in 323 patients with metastatic GIST on imatinib, sunitinib, or third-line tyrosine kinase inhibitors.57 As expected, patients with responsive disease at the time of surgery did the best, with a median PFS of 31 months after surgery. Patients with stable disease, unifocal progression, or multifocal progression at the time of surgery had a PFS of 19, 10, and 5 months, respectively \((P<0.001)\). Multifocal progression and a high tumor mitotic rate were independent predictors of worse PFS in a multivariable regression model. The subgroup of patients who were on imatinib at the time of surgery had a median PFS of 16 months. Within this subgroup, patients with responsive disease, stable disease, or unifocal progression at the time of surgery had a median PFS of 36, 30, and 11 months, respectively. The PFS of the patients with unifocal progression, in particular, compares favorably to a historical median PFS of <7 months (27 weeks) with sunitinib in the large Phase III trial, which would be the other option for these patients. These data suggest that it is reasonable to consider surgery on patients with advanced GIST responding to, stable on, or having unifocal progression on imatinib (Figure 4). However, only a Phase III trial can confirm whether or not these patients truly benefit from surgery plus imatinib versus imatinib alone. In contrast, in the subgroup of patients on sunitinib at the time of surgery \((n=93)\), radiographic response at the time of surgery was not significantly associated with PFS, and overall these patients had a poor median PFS of 7 months. This is likely reflective of more aggressive tumor biology and suggests that surgery should play a more limited role in patients who are already on second-line or further tyrosine kinase inhibitor therapy.

**Ongoing research into alternative strategies**

**Novel anti-tyrosine kinase agents**

Several novel anti-tyrosine kinase agents are currently being tested in Phase I clinical trials. PLX9486 is a tyrosine kinase inhibitor that was found in pre-clinical studies to be effective against patient-derived imatinib-resistant GIST xenografts in mice with both primary exon 9 and 11 mutations as well as secondary exon 17 and 18 mutations.63 PLX9486 did not have good activity against GISTs with KIT exon 13 or 14 mutations, but since tumors with these mutations respond to sunitinib, a Phase I clinical trial was designed to examine PLX9486 activity both alone and in combination with sunitinib or pexidartinib, another tyrosine kinase inhibitor with activity against KIT exon 13 and 14 mutations. The study enrolled 36 patients with metastatic GIST on at least second-line tyrosine kinase inhibitor therapy, and the investigators reported a median PFS of >24 weeks with PLX9486 alone, and a PFS not yet reached for either combination.64

DCC-2618 is a tyrosine kinase inhibitor that inhibits the switch pocket adjacent to the ATP domain of both KIT and PDGFRA. It has been shown to broadly inhibit the activity of all KIT mutants.65 A Phase I clinical trial of DCC-2618 in patients with metastatic GIST on at least second-line therapy found that patients treated with DCC-2618 had a median PFS of 24 weeks.66 DCC-2618 is currently being investigated in the fourth-line setting in a randomized Phase III trial (INVICTUS, NCT03353753).

As previously discussed, advanced GISTs with PDGFR A D842V mutations are particularly challenging to treat due to their inherent imatinib resistance. Avaparatinib (BLU-285) is a novel inhibitor that specifically targets KIT exon 17 and PDGFR A D842 mutations.67 A Phase I trial (NAVIGATOR)
has enrolled 231 patients with advanced GIST either with a PDGFRA D842V mutation (n=56) or progression on at least second-line tyrosine kinase inhibitor therapy. Preliminary results, which were presented at the 2018 Connective Tissue Oncology Society meeting, showed a remarkable 86% response rate in patients with PDGFRA D842V mutations, with 8 complete responses by RECIST 1.1, while the other subgroups, including patients on fourth-line therapy or further, had response rates of 20–26%.\(^{58}\) Currently, avapritinib is being compared to regorafenib in the third- or fourth-line setting in a Phase III randomized trial (VOYAGER, NCT03465722).

**Other targeted therapy**

The overall diminishing returns of switching from one tyrosine kinase inhibitor to another highlights the need for alternative therapeutic strategies against GIST. Some groups are investigating combining imatinib with inhibition of other molecules further downstream in the KIT signaling pathway. Floris and colleagues assessed the effect of imatinib plus the PI3K inhibitor GDC-0941 on the growth of human GIST xenografts in mice. They found that combination therapy induced significantly more tumor regression compared to imatinib alone, and furthermore that tumor regression was sustained after withdrawal of combination therapy, while tumors treated with imatinib alone regrew after cessation of therapy.\(^{69}\) Chi and colleagues showed that high levels of the transcription factor ETV1 cooperate with KIT to enhance GIST tumorigenesis from ICC precursors.\(^{70}\) Furthermore, in human GIST cell lines and xenograft mouse models, dual inhibition of ETV1 and KIT was more effective than inhibition of KIT alone.\(^{71}\)

As previously discussed, wild-type GISTs tend to be imatinib-resistant. However, a small proportion of wild-type GISTs that are also SDH-proficient harbor an \(ETV6-NTRK3\) gene fusion.\(^{72}\) A recent Phase II study of larotrectinib, a TRK inhibitor, enrolled 55 patients with TRK-fusion-positive cancers. Three patients had TRK-fusion-positive GIST, of whom 2 achieved a partial response and 1 achieved a complete response.\(^{73}\) While TRK-fusion-positive tumors represent a small proportion of GISTs, the response rates are impressive and highlight the growing importance of molecular tumor characterization in guiding GIST therapy.

**Immunotherapy**

There appears to be a good rationale for immunotherapy in GIST, either alone or in combination with KIT inhibition, based on several preclinical studies. The presence of high immune infiltration of GIST specimens is predictive of PFS.\(^{74}\) In addition, imatinib seems to increase anti-tumor T-cell responses in GIST mouse models. Balachandran and colleagues found that imatinib treatment of a mouse model that develops spontaneous GISTs increased CD8\(^+\) T cell activation within the tumor and induced regulatory T cell apoptosis. This immunogenic effect seemed to occur through imatinib inhibition of tumor cell expression of Ido, an immunosuppressive enzyme.\(^{75}\)

Unfortunately, clinical results so far have been modest at best for GIST. In a Phase I trial by D’Angelo and colleagues, 28 patients with advanced sarcoma (of which 20 were GIST) were treated with dasatinib plus the CTLA-4 inhibitor ipilimumab. There were no partial or complete responses by RECIST, although there were 7 partial responses by Choi criteria in 13 GIST patients in which this was evaluable. Further research is needed to identify GIST patients that would be most likely to benefit from immunotherapy, and also to determine what the optimal regimen for these patients is.

**Summary and conclusions**

Current therapeutic strategies for GIST revolve around targeted therapy against KIT and PDGFRA. As experience with imatinib and other tyrosine kinase inhibitors has increased, clinicians have also been able to identify genotypic predictors of response and resistance to therapy to tailor targeted therapies for individual patients. The mutations with the most robust associations with response to imatinib include \(PDGFRA\) D842V (imatinib resistance), \(KIT/PDGFRA\) WT (imatinib resistant), and \(KIT\) exon 9 mutations (partial imatinib resistance, responds to higher-dose imatinib). There are other associations between mutational status and response to therapy, as summarized in Table 2, but they are often derived from smaller studies and have more limited clinical applicability at this time.

For patients with available mutational profiling, Figure 3 summarizes the current management of resectable GIST, and Figure 4 summarizes the management of metastatic or unresectable GIST. Currently, the outcomes for patients with advanced GIST are still quite poor, and there is an urgent need for novel therapeutic strategies. There has been some promise in novel tyrosine kinase inhibitors, non-tyrosine kinase-targeted therapy, and immunotherapy, but further research into these avenues is required.
Table 2 Treatment implications of KIT and PDGFRA mutations

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Treatment implication</th>
</tr>
</thead>
<tbody>
<tr>
<td>KIT exon 11</td>
<td>Imatinib sensitive,7,6 regorafenib sensitive77</td>
</tr>
<tr>
<td>KIT exon 9</td>
<td>Responsive to higher-dose imatinib,7,6 sunitinib sensitive40</td>
</tr>
<tr>
<td>Secondary KIT mutations (exons 13, 14, 17, 18)</td>
<td>Sunitinib sensitive40</td>
</tr>
<tr>
<td>PDGFRA D842V (exon 18)</td>
<td>Imatinib resistant,16 dasatinib sensitive52</td>
</tr>
<tr>
<td>KIT/PDGFRα WT</td>
<td>Imatinib resistant,21 regorafenib sensitive* (if SDH-deficient),77 dasatinib sensitive52</td>
</tr>
</tbody>
</table>

Note: *Patient numbers in these studies were low.

Abbreviation: SDH, succinyl dehydrogenase.

Disclosure

The authors report no conflicts of interest in this work.

References

The great majority of GISTs with PDGFRA mutations represent gastric static gastrointestinal stromal tumors with or without a mesenchymal \textit{mesenchymal} or an \textit{intermediate} risk. Adjuvant imatinib significantly improved oncologic outcome for metastatic/recurrent operable gastrointestinal stromal tumor (GIST): the PERSIST-5 clinical trial. \textit{JAMA Oncol}, 2018, e184060. doi:10.1001/jama.2018.4060


Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. \textit{Lab Invest}, 2004;84:874–883. doi:10.1038/labinvest.3700122


64. Wagner AJ, Tap WD, Shields AF, et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pixieltinib (pexi) or sunitinib (su) in patients (Pts) with advanced solid tumors and gastrointestinal stromal tumor (GIST). J Clin Oncol. 2018;36(15_suppl):11095.